Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
featured
Published in Metastatic Breast Cancer and
1 other channel

Expert Opinion / Interview · July 21, 2022

Fulvestrant or Exemestane Plus Ribociclib After Anti-Estrogen Therapy Plus CDK 4/6 Inhibition for HR+/HER2- Breast Cancer

Sara Tolaney MD, MPH

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Sara Tolaney MD, MPH

Further Reading

Related Videos